Stock Events

Stock Events

Lakefront Biotherapeutics NV 

$26.24
238
+$0.00+0% Thursday 14:23

Statistics

Day High
26.2
Day Low
26.2
52W High
34
52W Low
26.2
Volume
190
Avg. Volume
0
Mkt Cap
1.72B
P/E Ratio
5.77
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-3.6
-2.3
-1
0.3
Expected EPS
-0.462734154
Actual EPS
N/A

Financials

30.01%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.3BRevenue
389.73MNet Income

Analyst Ratings

28.33Average Price Target
The highest estimate is 33.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLPGF. It's not an investment recommendation.
ASML NV
21
ASML.AS
Shell
20
SHELL.AS
Prosus NV
18
PRX.AS
Alibaba Group
17
BABA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where both companies are developing treatments.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences collaborates with Galapagos on filgotinib but also competes in other areas of biopharmaceuticals, including antiviral drugs.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the immunology space, particularly in treatments for rheumatoid arthritis, where Galapagos also has interests.
AMGEN
AMGN
Mkt Cap224.63B
Amgen competes in the biotech space, focusing on innovative therapeutics, including areas like inflammation where Galapagos is active.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is involved in developing treatments for conditions like asthma and arthritis, directly competing with Galapagos' pipeline.
Biogen
BIIB
Mkt Cap31B
Biogen competes in the area of biopharmaceuticals with a focus on neurodegenerative diseases, an area Galapagos has shown interest in.
Novartis
NVS
Mkt Cap286.78B
Novartis competes across a broad range of therapeutic areas, including those targeted by Galapagos, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap152.69B
Pfizer operates in various therapeutic areas, including inflammation and immunology, competing with Galapagos' research and development efforts.
Merck
MRK
Mkt Cap335.14B
Merck & Co. competes in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Galapagos' interests.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca competes in multiple areas, including respiratory diseases, where Galapagos also focuses its research efforts.

About

Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
Show more...
CEO
Henry O. Gosebruch
Employees
452
Country
Belgium
ISIN
BE0003818359
WKN
000A0EAT9

Listings

BR
BE
LKFT.BR
AS
NL
LKFT.AS
SA
BR
LKFT34.SA
MU
DE
GXE.MU

0 Comments

Share your thoughts

FAQ

What is Lakefront Biotherapeutics NV stock price today?▼
The current price of GLPGF is $26.24 USD — it has increased by +0% in the past 24 hours. Watch Lakefront Biotherapeutics NV stock price performance more closely on the chart.
What is Lakefront Biotherapeutics NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Lakefront Biotherapeutics NV stocks are traded under the ticker GLPGF.
Is Lakefront Biotherapeutics NV stock price growing?▼
GLPGF stock has risen by +0% compared to the previous week, the month change is a -6.55% fall, over the last year Lakefront Biotherapeutics NV has showed a -8.35% decrease.
What is Lakefront Biotherapeutics NV market cap?▼
Today Lakefront Biotherapeutics NV has the market capitalization of 1.72B
When is the next Lakefront Biotherapeutics NV earnings date?▼
Lakefront Biotherapeutics NV is going to release the next earnings report on November 12, 2026.
What were Lakefront Biotherapeutics NV earnings last quarter?▼
GLPGF earnings for the last quarter are -0.23 USD per share, whereas the estimation was -0.14 USD resulting in a -62.15% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lakefront Biotherapeutics NV revenue for the last year?▼
Lakefront Biotherapeutics NV revenue for the last year amounts to 1.3B USD.
What is Lakefront Biotherapeutics NV net income for the last year?▼
GLPGF net income for the last year is 389.73M USD.
How many employees does Lakefront Biotherapeutics NV have?▼
As of August 18, 2026, the company has 452 employees.
In which sector is Lakefront Biotherapeutics NV located?▼
Lakefront Biotherapeutics NV operates in the Health & Wellness sector.
When did Lakefront Biotherapeutics NV complete a stock split?▼
Lakefront Biotherapeutics NV has not had any recent stock splits.
Where is Lakefront Biotherapeutics NV headquartered?▼
Lakefront Biotherapeutics NV is headquartered in Mechelen, Belgium.